安罗替尼联合放疗治疗非小细胞肺癌脑转移瘤疗效分析

Clinical Analysis of Anlotinib Combined with Radiotherapy in the Treatment of Brain Metastases from Non-small-cell Lung Cancer

目的探讨安罗替尼联合放疗对比单独放疗治疗非小细胞肺癌(non-small-cell lung cancer,NSCLC)脑转移瘤的疗效差异。方法回顾性分析2018年7月~2020年12月徐州医科大学附属医院收治的NSCLC脑转移瘤患者资料,根据患者是否服用安罗替尼将其分为安罗替尼联合放疗组(联合组)和单独放疗组(放疗组),分析并比较两组患者的颅内无进展生存期、无进展生存期和总生存期。结果本研究共纳入患者71例,其中联合组26例,放疗组45例,1∶1倾向性匹配后获得26对患者。结果显示,联合组较放疗组延长了颅内无进展生存期(7.80个月vs 6.20个月,P=0.003)和无进展生存期(6.40个月vs 4.50个月,P=0.031),两组有相近的总生存期(12.20个月vs 9.80个月,P=0.086)。多因素COX回归分析结果显示,是否服用安罗替尼是颅内无进展生存期的影响因素(HR=2.00,P=0.003)。结论与单独放疗比较,安罗替尼联合放疗治疗NSCLC脑转移瘤有更好的生存获益。

Objective To investigate the efficacy of anlotinib combined with radiotherapy compared with radiotherapy alone in the treatment of brain metastases from non-small cell lung cancer(NSCLC). Methods Retrospective analysis was performed on the data of patients with NSCLC brain metastases admitted to The Affiliated Hospital of Xuzhou Medical University from July 2018 to December 2020, and they were divided into anlotinib combined radiotherapy group(combined group) and radiotherapy alone group(radiotherapy group) according to whether they were taking anlotinib or not. The intracranial progression-free survival, progression-free survival and overall survival were analyzed and compared between the two groups. Results A total of 71 patients were included in this study, including 26 patients in the combination group and 45 patients in the radiotherapy group. 26 pairs of patients were obtained after 1∶1 bias matching. Results showed that the combination group had longer intracranial progression-free survival(7.80 months vs 6.20 months, P=0.003) and progression-free survival(6.40 months vs 4.50 months, P=0.031) compared with the radiotherapy group, and the two groups had similar overall survival(12.20 months vs 9.80 months, P=0.086). Multivariate COX regression analysis showed that anlotinib was an influential factor in intracranial progression-free survival(HR=2.00, P=0.003). Conclusion Anlotinib combined with radiotherapy in the treatment of brain metastases from NSCLC had a better survival benefit than radiotherapy alone.